SOURCE: Xpention Genetics, Inc.

April 13, 2005 18:58 ET

Bayview Corporation Effects Name Change and Forward Split

CONIFER, CO -- (MARKET WIRE) -- April 13, 2005 -- Xpention Genetics Inc. (OTC BB: XPNG), formerly Bayview Corporation (OTC BB: BYVW), completes name change and thirteen for one forward split. The name change and stock split was effective Tuesday, April 12, 2005.

The name change reflects the Company's acquisition of Xpention, Inc. and the change of business. Xpention, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods for both animal and human cancers.

David Kittrell, CEO, commented, "We are extremely excited to enter the public market. I believe shareholders will benefit greatly from our business combination which will trade on the Over-The-Counter Bulletin Board as Xpention Genetics, Inc."

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.

Contact Information